Correspondence 0001213900-23-054343 from Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936) (CYTOF)

Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936)
Date: July 5, 2023 · CIK: 0001601936 · Accession: 0001213900-23-054343

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-272741

Date

July 5, 2023

Author

H.C. WAINWRIGHT & CO., LLC

Form

CORRESP

Company

Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936)

Letter

Re:

July 5, 2023

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

100 F Street, N.E.

Washington, DC 20549

Altamira Therapeutics Ltd.

Registration Statement on Form F-1 (Registration No. 333-272741), as amended - Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best efforts basis in an offering pursuant to the registration statement on Form F-1 (333-272741) (the “Registration Statement”), hereby concurs in the request by Altamira Therapeutics Ltd. that the effective date of the above-referenced registration statement be accelerated to 5:15 P.M. (Eastern Time), or as soon as practicable thereafter, on Wednesday July 5, 2023, pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”). Wainwright affirms that it is aware of its obligations under the Securities Act as they pertain to the best efforts offering pursuant to the Registration Statement.

Very truly yours,
H.C. WAINWRIGHT & CO., LLC

Show Raw Text

CORRESP
1
filename1.htm

July 5, 2023

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

100 F Street, N.E.

Washington, DC 20549

    Re:

    Altamira Therapeutics Ltd.

    Registration Statement on Form F-1 (Registration No. 333-272741),
as amended - Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co.,
LLC (“Wainwright”), solely acting as placement agent on a best efforts basis in an offering pursuant to the registration
statement on Form F-1 (333-272741) (the “Registration Statement”), hereby concurs in the request by Altamira Therapeutics
Ltd. that the effective date of the above-referenced registration statement be accelerated to 5:15 P.M. (Eastern Time), or as soon as
practicable thereafter, on Wednesday July 5, 2023, pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities
Act”). Wainwright affirms that it is aware of its obligations under the Securities Act as they pertain to the best efforts offering
pursuant to the Registration Statement.

    Very truly yours,

    H.C. WAINWRIGHT & CO., LLC

    By:
    /s/ Mark W. Viklund

    Name:
     Mark W. Viklund

    Title:
     Chief Executive Officer

SecProbe.io